aprevo平台

Search documents
高盛精选两大潜力股:AI营销平台Braze(BRZE.US)与医疗科技Carlsmed(CARL.US)获“买入“评级
智通财经网· 2025-09-15 01:33
Group 1: Market Overview - The stock market has rebounded strongly from the sharp decline in April, reaching a historical high, with the S&P 500 index up 11% and the Nasdaq index up 13.5% year-to-date, reflecting sustained market optimism [1] - Goldman Sachs' Chief U.S. Equity Strategist David Kostin predicts that the upcoming Federal Reserve interest rate cuts and a projected acceleration in economic growth in 2026 will support further gains in U.S. equities [1] - Kostin's forecast includes three expected interest rate cuts by the Federal Reserve this year and a prediction that the U.S. economy will avoid recession, with the S&P 500 index expected to rise by 2% by year-end and 6% by mid-2026 [1] Group 2: Braze (BRZE.US) - Braze operates a customer engagement platform for multi-channel marketing optimization, focusing on conversation rather than sales, and aims to provide a clear path from information acquisition to comfortable purchasing [2] - The platform is data-driven and AI-enabled, allowing enterprise clients to interact with users and convert sales funnels into information journeys, processing over 3.9 trillion messages last year [2] - For the second quarter of fiscal year 2026, Braze reported revenue of $180.1 million, a 24% year-over-year increase, exceeding expectations by nearly $8.5 million, with a non-GAAP EPS of $0.15, surpassing estimates by $0.12 [3] - Goldman Sachs analysts view Braze as a preferred stock with a target price of $52, indicating a potential upside of 73% over the next year [3] Group 3: Carlsmed (CARL.US) - Carlsmed focuses on AI-driven personalized spinal surgery, aiming to reduce surgical costs while improving patient outcomes, with its aprevo platform supporting precise surgical planning [4] - The company went public on July 22, pricing its IPO at $15 per share and raising approximately $100.5 million [4] - For the second quarter of fiscal year 2025, Carlsmed reported revenue of $12.1 million, a significant 99% increase year-over-year, with guidance for full-year revenue between $45.5 million and $47.5 million [5] - Goldman Sachs analysts highlight Carlsmed's growth potential driven by expected sales team expansion and the launch of cervical indications in 2026, projecting a target price of $19, indicating a 40% upside [5]